BTK inhibitor
Sanofi’s Rilzabrutinib Shows Promising Results in Phase III Trial for Immune Thrombocytopenia (ITP)
Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study
Actionable Insights Powered by AI
Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study